Design Therapeutics Inc (DSGN) - Biznesning o‘zini qoplash muddati

Design Corp (DSGN) brendining ramzi va logotipi

Design Therapeutics (DSGN) mushak patologiyalariga qarshi kurashish uchun AQShga asoslangan innovatsion fundamentga tayanadi. Loyihaning muvaffaqiyati kichik molekulalarning samaradorligini tasdiqlashga bog'liq, aksda esa aksiya narxlari kotirovkalari grafikda ko'rsatilgan GURU.Markets platformasidagi P/E ko'rsatkichi -9.20 darajasida turibdi. Xatarlar xalqaro patentlash va global beqarorlik sharoitida xomashyo xarididagi logistik murakkabliklar bilan bog'liq.

DSGN Design Therapeutics Inc Narxning foydaga nisbati (04.07.2022 - 12.11.2026)

Design Pharma (DSGN) kompaniyasining tahliliy kesimlari

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Birja grafigi designtx.com|DSGN - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi ko'rsatkichlari:
Bozor kapitallashuvi Design Therapeutics, Inc.|DSGN - Korxona qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Yagona aksiya balans qiymati Design Therapeutics|DSGN - Kompaniyaning balans qiymati|Kapitallashuvning balans qiymatiga nisbati designtx.com|DSGN - Kompaniyaning yakuniy aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Barcha qarzlarning o‘z mablag‘lariga nisbati Design Therapeutics|DSGN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli kreditlarning kapitalga nisbati Design Corp|DSGN - Kompaniyaning jamlangan qarzlari|Qarzning sof aktivlarga nisbati Design Therapeutics, Inc.|DSGN - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Design Therapeutics|Oraliq qoplash koeffitsiyenti designtx.com
- foyda va multiplikatorlar bo'yicha ma'lumotlar:
DSGN - Sof foyda|Prognoz qilingan kelajakdagi foyda Design Therapeutics|DSGN - Narxning foydaga nisbati|Narxning kutilayotgan foydaga nisbati Design Therapeutics Inc|DSGN - PEG multiplikatori|Kompaniya qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati Design Therapeutics, Inc.|DSGN - Eskirish chegirilmasdan oldingi operatsion foyda|Bir aksiya uchun sof foyda (EPS TTM) Design Therapeutics|DSGN - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi o'n ikki oy davomida bir aksiya uchun foydaning yillik o'sish sur'ati designtx.com|DSGN - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi Design Therapeutics
Kompaniyaning jamlanma tahlili:designtx.com - DSGN
Design Therapeutics Inc yetakchi tovari

Uzoq muddatli investitsiyalar kapital yo'qotish risklarini minimallashtirish uchun tebranishlarning qat'iy monitoringini talab qiladi. Design Therapeutics (DSGN) uchun bu holat baholashning GeneTAC platformasi va Fridreyx ataksiyasi terapiyasi muvaffaqiyatiga bog'liqligi sababli juda muhimdir. Kompaniyaning maqsadli P/E ko'rsatkichini tahlil qilish orqali investor kelajakdagi o'sish uchun to'langan premiumni aniqlash uchun bozor narxining sof foydaga nisbatini baholaydi. Ushbu ko'rsatkich joriy kotirovkani biotexnologiya biznesining haqiqiy fundamental qiymati bilan aniq sinxronizatsiya qilish imkonini beradi.

Muhim raqobatchilar

Tempus AI Inc (TEM) - Biznesning o‘zini qoplash muddati|P/E multiplikatori QGEN|Biznesning o‘zini qoplash muddati Ionis Pharmaceuticals, Inc.|P/E multiplikatori RGEN (Repligen Corp.)|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Avidity Corp|CRSP - Narxning foydaga nisbati|WGS (genedx.com) - Narx-foyda multiplikatori|RARE (Ultragenyx) - Narx-foyda koeffitsiyenti|Beam Therapeutics Inc - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti SRPT|TWST (Twist Bioscience Corp) - Bozor narxining sof foydaga nisbati|P/E multiplikatori TXG|NTLA (intelliatx.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori STOK (Stoke Therapeutics, Inc.)|BioLife Solutions Inc (BLFS) - Kapitalizatsiyaning foydaga nisbati|WVE - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati MAZE (Maze Therapeutics Corp)|SION: P/E multiplikatori|primemedicine.com (PRME) - P/E multiplikatori|Narxning foydaga nisbati Taysha Gene Therapies, Inc.|uniQure NV - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori MGTX|RGNX - Kapitalizatsiyaning foydaga nisbati|Solid Biosciences Inc. - Narx-foyda koeffitsiyenti|P/E multiplikatori ocugen.com OCGN|PACB: Narx-foyda koeffitsiyenti|Benitec Biopharma Inc - Bozor narxining sof foydaga nisbati|RCKT: P/E multiplikatori|FDMT - Biznesning o‘zini qoplash muddati|LXEO (Lexeo Therapeutics Inc.) - P/E multiplikatori|Narx-foyda koeffitsiyenti Korro Bio, Inc (KRRO)|Narxning foydaga nisbati Editas Medicine (EDIT)|Biznesning o‘zini qoplash muddati Silence Therapeutics PLC|P/E multiplikatori PRQR (ProQR Therapeutics)|CDXS: Narx-foyda multiplikatori|SGMO - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Nautilus Biotechnology NAUT|MGX: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti precisionbiosciences.com DTIL|Narxning foydaga nisbati Generation Bio Co|Narx-foyda multiplikatori BOLD (Boundless Bio Inc)|P/E multiplikatori XCUR|imunon.com - Narx-foyda multiplikatori|Narxning foydaga nisbati Phio Pharmaceuticals Corp. PHIO|MBIO: Narx-foyda multiplikatori|TransCode - P/E multiplikatori|BNGO - P/E multiplikatori|APDN: P/E multiplikatori|Narx-foyda multiplikatori BLUE|IPA (ImmunoPrecise Antibodies Ltd) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Omega Therapeutics Inc OMGA|Narxning foydaga nisbati Singular Genomics Systems Inc (OMIC)|Biznesning o‘zini qoplash muddati Regulus|P/E multiplikatori SYRS (Syros Pharmaceuticals)|Biznesning o‘zini qoplash muddati telesisbio.com (TBIO)|TRACON Pharmaceuticals, Inc. - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Unity Biotechnology Inc. (UBX)